These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 35756967)

  • 21. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
    Zimmer AS; Denduluri N
    Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.
    Gunasekara ADM; Anothaisintawee T; Youngkong S; Ha NT; McKay GJ; Attia J; Thakkinstian A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer.
    Abdel-Razeq H; Khalil H; Assi HI; Dargham TB
    Curr Oncol; 2022 Aug; 29(8):5810-5822. PubMed ID: 36005196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.
    Sussell JA; Roth JA; Meyer CS; Fung A; Hansen SA
    Adv Ther; 2022 Mar; 39(3):1375-1392. PubMed ID: 35094298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
    Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
    [No Abstract]   [Full Text] [Related]  

  • 26. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant treatment for HER2-positive breast cancer.
    Takada M; Toi M
    Chin Clin Oncol; 2020 Jun; 9(3):32. PubMed ID: 32527117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
    Huang CS; Yang Y; Kwong A; Chen SC; Tseng LM; Liu MC; Shen K; Wang S; Ng TY; Feng Y; Sun G; Yan IR; Shao Z
    Breast Cancer Res Treat; 2021 Jun; 187(3):759-768. PubMed ID: 33860389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
    Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
    Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.
    Batoo S; Bayraktar S; Al-Hattab E; Basu S; Okuno S; Glück S
    J Carcinog; 2019; 18():5. PubMed ID: 31949426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
    Kolberg HC; Akpolat-Basci L; Stephanou M; Aktas B; Hannig CV; Liedtke C
    Breast Care (Basel); 2016 Oct; 11(5):323-327. PubMed ID: 27920624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Pernas S; Tolaney SM
    JCO Oncol Pract; 2021 Jun; 17(6):320-330. PubMed ID: 34111378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.
    Advani P; Cornell L; Chumsri S; Moreno-Aspitia A
    Breast Cancer (Dove Med Press); 2015; 7():321-35. PubMed ID: 26451122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
    Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.